MARKET

RMTI

RMTI

Rockwell Medical
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.545
+0.120
+8.42%
Opening 12:44 02/24 EST
OPEN
1.440
PREV CLOSE
1.425
HIGH
1.550
LOW
1.430
VOLUME
584.37K
TURNOVER
--
52 WEEK HIGH
3.850
52 WEEK LOW
0.8300
MARKET CAP
144.57M
P/E (TTM)
-3.5673
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
How to trade Rockwell Medical $RMTI With Risk Controls
Price matters most to making money in the market. Celebrating 20 years, Stock Traders Daily provides the tools that help you develop investment strategies,...
Stock Traders Daily · 02/11 09:06
Intravenous (IV) Iron Drugs Market 2021 : Revenue Data, Key Manufacturers, Historic and Forecast Analysis with Top Countries Data
Feb 09, 2021 (The Expresswire) -- Global “Intravenous (IV) Iron Drugs Market" 2021-2026 Research Report provides key analysis on the market status of the...
The Express Wire · 02/10 01:41
Rockwell Could Face Covid-19 Headwinds, but the Stock Is a ‘Buy,’ Says Analyst
TipRanks.com · 02/09 18:45
BRIEF-Rockwell Medical Announces U.S. Availability Of Triferic Avnu For Replacement Of Iron
reuters.com · 02/09 12:16
Rockwell Medical Announces U.S. Availability of Triferic AVNU for Replacement of Iron and Maintenance of Hemoglobin in Patients on Hemodialysis
Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced
Benzinga · 02/09 12:04
Nephrology And Urology Devices Market Share Analysis, Key Growth Drivers, Challenges, Leading Key Players Review, Demand and Upcoming Trend by Forecast to 2026
Feb 09, 2021 (The Expresswire) -- The Nephrology And Urology Devices industry has undergone many changes in recent years and expects numerous variations in...
The Express Wire · 02/09 06:21
DJ Rockwell Medical Price Target Cut to $5.50/Share From $9.00 by HC Wainwright & Co.
Dow Jones · 02/08 11:57
DJ Rockwell Medical Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/08 11:57
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RMTI. Analyze the recent business situations of Rockwell Medical through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RMTI stock price target is 5.25 with a high estimate of 5.50 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 159
Institutional Holdings: 25.63M
% Owned: 27.39%
Shares Outstanding: 93.57M
TypeInstitutionsShares
Increased
32
3.54M
New
22
401.30K
Decreased
19
7.43M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.70%
Pharmaceuticals & Medical Research
+1.40%
Key Executives
Chairman/Independent Director
John McLaughlin
President/Chief Executive Officer/Director
Russell Ellison
Chief Financial Officer/Executive Vice President
Russell Skibsted
Senior Vice President
Jim McCarthy
Chief Accounting Officer/Vice President/Controller
Paul McGarry
Chief Scientific Officer
Ajay Gupta
Vice President - Operations
Michael DeYoung
Other
Marc Hoffman
Other
Raymond Pratt
Independent Director
John Cooper
Independent Director
Robert Radie
Independent Director
David Domzalski
Independent Director
Mark Ravich
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About RMTI
Rockwell Medical, Inc. is a biopharmaceutical company. The Company is targeting end-stage renal disease and chronic kidney disease with products for the treatment of iron deficiency and hemodialysis. The Company is also a manufacturer of hemodialysis concentrates for dialysis providers and distributors. The Company’s renal drug therapy, Triferic, supports disease management initiatives. Triferic is therapy indicated to replace iron and maintain hemoglobin in hemodialysis patients via dialysate during each dialysis treatment. The Company has developed multiple formulations of Triferic: Dialysate Triferic and Intravenous Triferic (I.V. Triferic). Dialysate Triferic is the therapeutic indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.

Webull offers kinds of Rockwell Medical Inc stock information, including NASDAQ:RMTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RMTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RMTI stock methods without spending real money on the virtual paper trading platform.